Sino Biopharmaceutical Limited

Overview

Compare with another stock.

• Ticker1177 on Hong Kong Stock Exchange¹
• HeadquartersHong Kong, Hong Kong¹
• Websitewww.sinobiopharm.com
• Legal formexempt company³
• LEI529900LPR4ADFEJAR786³
• StatusActive³
• LEI statusIssued and current³
• Registered addressc/o CONYERS TRUST COMPANY (CAYMAN) LIMITED, P. O. Box 2681, CRICKET SQUARE, HUTCHINS DRIVE, KY1-1111 Grand Cayman, Cayman Islands³
• Registered withGeneral Registry, 96717³

See how the biggest companies compare on our leaderboards

Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司), shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China (Hong Kong-listed) 25 Index in 2020.²

Timeline

1. Dec 8, 2003Went public Listed on Hong Kong Stock Exchange¹
2. Feb 2, 2000Founded Sino Biopharmaceutical Limited is founded³

Calendar

Drug trials and FDA: coming up

1. Oct 2026Phase 3 trial readout expected Phase 3 trial of D-1553 Tablet and Docetaxel injection in Non Small Cell Lung Cancer: primary completion expected Oct 2026 (ClinicalTrials.gov NCT06300177).⁴
2. Dec 2026Phase 3 trial readout expected Phase 3 trial of AK105 Injection, Anlotinib Hydrochloride Capsules and others in Advanced Hepatocellular Carcinoma (HCC): primary completion expected Dec 2026 (ClinicalTrials.gov NCT04344158).⁵
3. Dec 2026Phase 3 trial readout expected Phase 3 trial of TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen in Breast Cancer: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05780567).⁶
4. Dec 2026Phase 3 trial readout expected Phase 3 trial of TQB3454 tablets in Biliary Carcinoma: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05987358).⁷
5. Jan 2027Phase 3 trial readout expected Phase 3 trial of TQB2102 for Injection and Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) in Breast Cancer: primary completion expected Jan 2027 (ClinicalTrials.gov NCT06561607).⁸
6. Jan 2027Phase 3 trial readout expected Phase 3 trial of AL2846 Capsules in Thyroid Cancer: primary completion expected Jan 2027 (ClinicalTrials.gov NCT06860971).⁹

Drug trials and FDA: recently

1. Apr 28, 2026Phase 2 trial completed Phase 2 trial of TQC3721 inhalation powder in Pulmonary Disease, Chronic Obstructive: primary completion Apr 28, 2026, no results posted yet (ClinicalTrials.gov NCT07252908).¹⁰
2. Mar 7, 2026Phase 3 trial completed Phase 3 trial of TQF3510 (Semaglutide Injection) and Wegovy® in Obesity: primary completion Mar 7, 2026, no results posted yet (ClinicalTrials.gov NCT06738979).¹¹
3. Dec 19, 2025Phase 2 trial completed Phase 2 trial of 300mg/600mg of TQH2722 injection in Chronic Rhinosinusitis: primary completion Dec 19, 2025, no results posted yet (ClinicalTrials.gov NCT06439381).¹²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• Websitewww.sinobiopharm.com¹
• WikipediaSino Biopharmaceutical Limited
• WikidataQ10874682